Drug Trial Radar · NCT01151423
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jan 2011
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- Ablynx, a Sanofi companyIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP. Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange (PE).
Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
Interventions
CaplacizumabBiological
* Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session). * The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure. * All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose. * Subjects received caplacizumab up to 30 days after the last PE session.
PlaceboBiological
* Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session). * The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure. * All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose. * Subjects received placebo up to 30 days after the last PE session.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µLTime frame: From the day of first study drug administration up to 30 days after first study drug administration
Locations
51 sites in 13 countries. Site status is shown where the registry gives one.
Investigator Site
Los Angeles, California
Investigator Site
Washington D.C., District of Columbia
Investigator Site
Atlanta, Georgia
Investigator Site
St Louis, Missouri
Investigator Site
New York, New York
Investigator Site
Rochester, New York
Investigator Site
Valhalla, New York
Investigator Site
Durham, North Carolina
Investigator Site
Winston-Salem, North Carolina
Investigator Site
Columbus, Ohio
Investigator Site
Pittsburgh, Pennsylvania
Investigator Site
Dallas, Texas
Investigator Site
Salt Lake City, Utah
Investigator Site
Liverpool, Australia
Investigator Site
Melbourne, Australia
Investigator Site
Woolloongabba, Australia
Investigator Site
Garran, Australian Capital Territory, Australia
Investigator Site
Graz, Austria
Investigator Site
Vienna, Austria
Investigator Site
Antwerp, Belgium
Investigator Site
Brussels, Belgium
Investigator Site
Leuven, Belgium
Investigator Site
Namur, Belgium
Investigator Site
Sofia, Bulgaria
Investigator Site
Caen, France
Investigator Site
Aachen, Germany
Investigator Site
Berlin, Germany
Investigator Site
Cologne, Germany
Investigator Site
Dortmund, Germany
Investigator Site
Hanover, Germany
Investigator Site
Mainz, Germany
Investigator Site
Mannheim, Germany
Investigator Site
München, Germany
Investigator Site
Ulm, Baden-Wurttemberg, Germany
Investigator Site
Haifa, Israel
Investigator Site
Jerusalem, Israel
Investigator Site
Petah Tikva, Israel
Investigator Site
Catania, Italy
Investigator Site
Foggia, Italy
Investigator Site
Milan, Italy
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.